Education
About Us
Working with TipRanks
Follow Us
AstraZeneca (GB:0A4J)
:0A4J
0A4J Stock Chart & Stats
Day’s Range― - ―
52-Week Range$61.66 - $87.62
Previous CloseN/A
Volume5.36K
Average Volume (3M)30.00
Market Cap
$221.49B
Enterprise Value$255.81B
Total Cash (Recent Filing)$5.23B
Total Debt (Recent Filing)$31.29B
Price to Earnings (P/E)28.5
Beta1.10
Next Earnings
Jul 24, 2025EPS Estimate
1.1Last Dividend Ex-Date
Feb 21, 2025Dividend Yield2.11%
Share Statistics
EPS (TTM)1.25
Shares Outstanding3,101,276,900
10 Day Avg. Volume1
30 Day Avg. Volume30
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.15
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.83
Enterprise Value/Ebitda14.46
Forecast
1Y Price Target
$86.34Price Target Upside20.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsDESTINY-Breast09 demonstrated a highly statistically significant and clinically meaningful improvement in PFS for Enhertu + pertuzumab vs the control arm standard of care in patients with 1L HER2+ metastatic breast cancer.
Financial PerformanceThe company reported product revenues of $13.362bn, beating consensus estimates of $13.050bn by ~2%.
Pipeline And ProductsAZN has promising new products and pipeline, and participates in many large, high-growth markets.
Bears Say
China Business RisksCurrent investor concerns mainly revolve around risks to the China business due to alleged improper practices by former employees.
Product SalesTotal Product Sales of $12,875 bn missing consensus estimates by ~2% and missing Leerink Partners' estimate by ~1%.
Sales PerformanceDecreasing roxadustat China sales are expected in subsequent years due to expected VBP inclusion.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
5.78%
Mutual Funds
0.12% Other Institutional Investors
93.18% Public Companies and
Individual Investors
0A4J FAQ
What was AstraZeneca’s price range in the past 12 months?
AstraZeneca lowest share price was $61.66 and its highest was $87.62 in the past 12 months.
What is AstraZeneca’s market cap?
AstraZeneca’s market cap is $221.49B.
When is AstraZeneca’s upcoming earnings report date?
AstraZeneca’s upcoming earnings report date is Jul 24, 2025 which is in 78 days.
How were AstraZeneca’s earnings last quarter?
AstraZeneca released its earnings results on Apr 29, 2025. The company reported $1.245 earnings per share for the quarter, beating the consensus estimate of $1.116 by $0.129.
Is AstraZeneca overvalued?
According to Wall Street analysts AstraZeneca’s price is currently Undervalued.
Does AstraZeneca pay dividends?
AstraZeneca pays a Semiannually dividend of $1.519 which represents an annual dividend yield of 2.11%. See more information on AstraZeneca dividends here
What is AstraZeneca’s EPS estimate?
AstraZeneca’s EPS estimate is 1.1.
How many shares outstanding does AstraZeneca have?
AstraZeneca has 3,101,276,900 shares outstanding.
What happened to AstraZeneca’s price movement after its last earnings report?
AstraZeneca reported an EPS of $1.245 in its last earnings report, beating expectations of $1.116. Following the earnings report the stock price went up 0.86%.
Which hedge fund is a major shareholder of AstraZeneca?
Currently, no hedge funds are holding shares in GB:0A4J
---
AstraZeneca Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$86.34 (20.54% Upside)
$86.34 (20.54% Upside)
Blogger Sentiment
Bullish
GB:0A4J Sentiment 70%
Sector Average 71%
Sector Average 71%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-5.39%
12-Months-Change
Fundamentals
Return on Equity
19.81%
Trailing 12-Months
Asset Growth
3.87%
Trailing 12-Months
Company Description
AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
---
0A4J Company Deck
---
0A4J Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong start to 2025 with significant revenue and EPS growth, driven by pipeline advancements and strategic global manufacturing. However, challenges such as Medicare Part D redesign and headwinds in China and Soliris revenue present areas of concern.Read More>---
0A4J Stock 12 Month Forecast
Average Price Target
$86.34
▲(20.54% Upside)
Technical Analysis
---